What Is a Pelvic Lymphadenectomy Procedure?

A pelvic lymphadenectomy is a surgical procedure in which a surgeon removes lymph nodes from the pelvis so they can be examined under a microscope for signs of cancer spread. The operation is performed alongside other cancer surgeries for cancers of the bladder, prostate, cervix, and uterus, and it serves two purposes: it tells doctors how far the disease has traveled, and it may remove cancer deposits that imaging never detected. The procedure sounds straightforward, but almost every aspect of it, from how many nodes to take to whether it genuinely extends life, remains a subject of active debate among surgeons and oncologists.

Why Surgeons Remove Pelvic Lymph Nodes

Cancers that start in pelvic organs tend to spread first to the lymph nodes nearby. Knowing whether cancer has reached those nodes changes almost every decision that follows: whether you need chemotherapy or radiation afterward, how aggressively doctors monitor you, and what your likely prognosis looks like. Without removing and examining the nodes, doctors are essentially guessing based on imaging, and imaging gets it wrong more often than you might expect. A multicenter study of patients with upper urinary tract cancer found that conventional scans correctly identified the node status only about 74% of the time, missing cancer in roughly one in five patients whose nodes turned out to be positive on pathology.

Beyond staging, there is growing evidence that removing affected nodes can itself improve outcomes. In bladder cancer, the National Comprehensive Cancer Network guidelines advocate pelvic lymph node dissection during radical cystectomy partly because data from large studies show better outcomes in patients who undergo the dissection compared with those who do not, regardless of whether the nodes turn out to be positive.

Which Cancers Call for It

Pelvic lymphadenectomy shows up across several cancer types, though the rationale and enthusiasm for it differ depending on the disease.

Bladder cancer: Radical cystectomy with pelvic lymph node dissection is the standard treatment for muscle-invasive bladder cancer. Up to a quarter of patients harbor metastatic deposits in their pelvic nodes at the time of surgery.

Prostate cancer: Guidelines generally agree that when a lymph node dissection is performed, an extended template is preferred. However, there is significant disagreement about which patients actually need one. Some guidelines suggest skipping it altogether in lower-risk patients, while others use risk calculators to decide.

Endometrial cancer: Surgical staging with lymph node sampling has been the standard since 1988, after reports showed it identified patients with disease that had spread beyond the uterus. Low-risk patients with small, well-differentiated tumors and shallow invasion can safely skip it.

⁴

Cervical cancer: The procedure is a routine component of surgical treatment for cervical cancer, though sentinel lymph node approaches are increasingly being adopted as alternatives for early-stage disease.

The Anatomy of the Procedure

The pelvis contains several clusters of lymph nodes organized along major blood vessels and nerves. A classification system identifies five specific anatomic regions that surgeons work through: the external iliac, obturator, internal iliac, common iliac, and presacral areas. Running through or near these zones are important nerves, including the genitofemoral nerve, the obturator nerve, and parts of the lumbosacral plexus. Damage to any of these during dissection can cause problems ranging from thigh numbness to muscle weakness.

⁵

In a standard or limited dissection, the surgeon focuses on the nodes around the external iliac vessels and inside the obturator fossa, which is the area most likely to harbor metastases from pelvic cancers. An extended dissection pushes the boundaries further, sweeping up to the common iliac vessels and sometimes into the presacral area. In some cases, particularly for endometrial or cervical cancer, the dissection extends above the pelvis to include para-aortic nodes along the main abdominal blood vessels.

Open, Laparoscopic, or Robotic

Pelvic lymphadenectomy was traditionally performed through a large abdominal incision, and open surgery remains common when combined with major procedures like radical cystectomy. But minimally invasive approaches have steadily gained ground. A comparison of robotic versus laparoscopic pelvic lymphadenectomy for endometrial cancer found that robotic surgery took longer in the operating room (a median of about 316 minutes versus 272 minutes) but came with less blood loss and shorter hospital stays. The median stay after robotic surgery was five days compared with eight days for the laparoscopic group, with no significant difference in complications or cancer recurrence between the two approaches.

⁶

Robotic surgery in particular has been gaining traction because it gives surgeons better visualization and more precise instrument control in the tight confines of the pelvis. Reviews of the literature suggest robotic lymph node dissection can match or improve upon the quality of open and laparoscopic approaches, with benefits including less postoperative pain and better cosmetic outcomes, without compromising how many nodes are retrieved or how thoroughly the area is cleared.

⁷

Standard Versus Extended Dissection

One of the most debated questions in this area is how far the dissection should go. In prostate cancer, an extended dissection retrieves more nodes and catches more cases of cancer spread. One study found that the rate of positive nodes was 20% in patients who had an extended dissection versus 6% in those who had a standard one. That sounds like a clear win for the extended approach, except for one complication: when the researchers looked at cancer recurrence rates, they found no difference between the two groups at three years. Even in subgroup analyses of patients with positive nodes or high-grade disease, the extended dissection did not translate into lower recurrence.

⁸

A multi-institutional study went even further, comparing extended dissection to no dissection at all in patients with high-risk or very high-risk prostate cancer. The matched analysis showed no significant difference in recurrence-free survival, progression to treatment-resistant disease, or overall survival between the two groups.

⁹

This does not mean the extended dissection is worthless. The patients whose nodes came back positive in the extended group were much more likely to receive additional treatment afterward, including hormone therapy and radiation. The argument is that the real value lies in accurate staging: by finding cancer the standard dissection would have missed, doctors can offer appropriate follow-up treatment. Whether that translates to longer survival in the long run remains unclear, and this uncertainty is why guidelines diverge so sharply on the topic.

When Removing More Nodes Does Seem to Help

The picture is different for some cancer types. In prostate cancer, a meta-analysis of studies comparing extended to limited dissections found that the extended approach was associated with better biochemical recurrence-free survival.

¹⁰

In endometrial cancer, a meta-analysis found that adding para-aortic lymph node dissection to the pelvic dissection improved overall survival for patients at intermediate or high risk of recurrence, but not for low-risk patients. That distinction matters clinically: it means the most extensive surgery benefits people whose cancers are most likely to spread, while sparing low-risk patients from unnecessary procedures.

¹¹

In bladder cancer, a retrospective study comparing patients who had a dissection with those who did not found that the five-year recurrence-free survival rate was about 84% in the dissection group versus roughly 72% in the non-dissection group, a meaningful gap.

¹²

Complications and What to Expect

Like any surgery, pelvic lymphadenectomy carries risks. The complications specific to this procedure generally fall into a few categories: lymphoceles (fluid collections that form where nodes were removed), lymphedema (chronic swelling in the legs), blood clots, and nerve or ureteral injury.

¹³

Lymphoceles are the most common issue. In a study of 264 gynecologic cancer patients who had pelvic lymphadenectomy, about 18% developed lymphoceles. Higher body weight and a larger number of removed nodes both increased the risk. Most lymphoceles resolve on their own, but roughly a quarter of the patients who developed them needed treatment for related complications such as infection or compression of nearby structures.

¹⁴

A study focusing on robot-assisted lymphadenectomy for cervical and endometrial cancer found a symptomatic lymphocele rate of about 10%, with symptoms typically appearing around two months after surgery. Nearly all the patients with symptomatic lymphoceles needed readmission, with a median hospital stay of about eight days. Most required drainage along with antibiotics.

¹⁵

Whether to leave a drain in the pelvis after surgery to prevent lymphoceles is another contested point. A Cochrane review found that when the pelvic lining was left open (which is the current trend), drainage actually increased the rate of both overall and symptomatic lymphoceles. At 12 months the rates equalized. The evidence suggests that drains do not reliably prevent the problem and may worsen it in some situations.

¹⁶

Lower Limb Lymphedema and How to Reduce It

Lymphedema, the chronic swelling that results from disrupted lymphatic drainage, is perhaps the most feared long-term consequence. It is not just cosmetic; it can limit mobility, cause recurrent infections, and significantly affect quality of life. Post-operative radiation therapy compounds the risk. A study of ovarian and uterine cancer patients found that those who received pelvic radiation after lymph node surgery had nearly double the odds of developing lymphedema.

¹⁷

Recent research has focused on both surgical technique and exercise to reduce the risk. A randomized trial tested whether a progressive resistance exercise program could prevent lymphedema after pelvic lymphadenectomy. Over two years, the rate of lower limb lymphedema was about 9% in patients assigned to the exercise program, compared with roughly 43% in the control group, a dramatic reduction. Compression stockings alone fell somewhere in between but did not reach statistical significance.

¹⁸

On the surgical side, a randomized trial found that preserving the circumflex iliac lymph nodes, a specific set of nodes at the lower end of the external iliac chain, significantly reduced lymphedema at two years. The metastasis rate in those particular nodes was low in cervical and early endometrial cancer, meaning surgeons could safely leave them in place without missing cancer.

¹⁹

Nerve injury is rarer but can be serious. The obturator nerve, which controls certain thigh muscles, runs directly through the dissection field. Case reports describe accidental transection during laparoscopic surgery, which requires immediate surgical repair.

²⁰

Sentinel Lymph Node Mapping as an Alternative

The idea behind sentinel lymph node mapping is simple: instead of removing all the nodes in a region, you identify and remove just the first nodes that drain the tumor. If those sentinel nodes are cancer-free, the reasoning goes, you can spare the patient a full dissection and its complications. The technique uses a tracer dye, most commonly indocyanine green (ICG), injected near the tumor. The dye travels through the lymphatic channels and lights up the first nodes it reaches under near-infrared imaging.

A systematic review of ICG-based sentinel node mapping in cervical cancer found that overall detection rates ranged from 88% to 100% across studies, with most above 90%. Bilateral detection, meaning successfully finding sentinel nodes on both sides of the pelvis, ranged more widely from about 74% to 99%. False-negative rates varied considerably, from 0% to about 23%, which is the main concern: if the technique misses a positive node, the patient could be under-staged and undertreated.

²¹

Sentinel node mapping is now widely accepted for early-stage cervical cancer and is gaining ground for low- and intermediate-risk endometrial cancer. It is not yet standard in prostate or bladder cancer, where the lymphatic drainage patterns are less predictable and the stakes of missing a positive node are considered higher.

What Pathologists Look for in the Removed Nodes

Once the nodes are out, the pathologist’s job is to determine whether any cancer cells are present. Standard examination involves slicing the node, placing it on a glass slide, and staining it. But standard staining can miss tiny deposits. Ultrastaging is a more intensive process that cuts additional thin slices from the node at intervals and uses special antibody stains that highlight cancer cells the eye might otherwise miss.

²²

This extra scrutiny matters. In a study of endometrial cancer patients whose pelvic nodes were initially called negative on standard staining, ultrastaging of nearly 300 nodes revealed hidden cancer in 30% of the patients examined, including one case of micrometastasis and one of isolated tumor cells that would otherwise have gone undetected.

²³

Ultrastaging is routine when sentinel lymph node mapping is used, since fewer nodes are removed and each one is examined more intensively. When a full lymphadenectomy is performed, ultrastaging every node would be prohibitively time-consuming, so it is generally reserved for sentinel nodes or cases where the clinical picture does not match the pathology results.

Can Advanced Imaging Replace Surgery

PSMA PET/CT scans, which target a protein found on prostate cancer cells, represent one of the most promising imaging advances for detecting lymph node metastases without surgery. But the technology has limits. The SALT trial, which evaluated PSMA PET/CT before extended pelvic lymph node dissection, found very high specificity (about 94%) but limited sensitivity (about 41%). That means a positive scan was almost always correct, but a negative scan missed more than half of the actual metastases. The conclusion was blunt: current PSMA imaging cannot replace diagnostic lymph node dissection.

²⁴

A more recent study in intermediate-risk prostate cancer patients painted a somewhat more optimistic picture. PSMA PET/CT achieved about 80% sensitivity and 87% specificity, with a very high negative predictive value of 99%, meaning that when the scan said the nodes were clean, it was almost always right. This raises the question of whether negative PSMA scans could eventually allow some patients to skip the dissection entirely, though the false-positive rate was considerable: only about 14% of patients flagged as positive on the scan actually had confirmed metastases on pathology.

²⁵

How Node Counts Shape Treatment Decisions

The number of nodes retrieved is not just a surgical performance metric; it directly influences whether cancer is detected. Research on prostate cancer found that the chance of finding positive nodes increases steadily as the node count goes up, and dissections that yielded fewer than ten nodes were so unlikely to catch positive nodes that they arguably should not have been performed at all.

In endometrial cancer, the results of the lymph node evaluation feed directly into decisions about whether a patient needs radiation after surgery. A study found that surgeons and radiation oncologists both take the extent of the lymphadenectomy into account when counseling women about follow-up treatment. A thorough dissection that comes back negative can spare a patient from radiation they might otherwise receive “just in case,” while a positive result clearly directs the addition of appropriate therapy.

²⁶

This is the core tension running through the entire debate about pelvic lymphadenectomy. The procedure carries real risks and costs, and for many patients the nodes come back clean and the dissection changes nothing. But for the subset whose nodes are positive, accurate staging can mean the difference between getting the right treatment and missing a window to control the disease. Surgeons, oncologists, and patients navigate that tradeoff every day, and the tools for making it more precise, from sentinel node mapping to PSMA imaging, are improving but have not yet solved the problem.